2. Search Result
Search Result
Results for "

SERM

" in MedChemExpress (MCE) Product Catalog:

35

Inhibitors & Agonists

11

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13556A
    Arzoxifene hydrochloride

    LY353381 hydrochloride; SERM III hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Arzoxifene (LY353381) hydrocloride is a selective estrogen receptor modulator that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol.
    Arzoxifene hydrochloride
  • HY-13757AS
    Tamoxifen-​d5

    ICI 47699-​d5; (Z)-Tamoxifen-d5; trans-Tamoxifen-d5

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen-d5 is a deuterium labeled Tamoxifen. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM). Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity[1][2].
    Tamoxifen-​d5
  • HY-13556
    Arzoxifene

    LY353381; SERM III

    		 Estrogen Receptor/ERR Metabolic Disease
    Arzoxifene (LY353381) is an orally active selective estrogen receptor modulator with a fixed ring structure similar to raloxifene. Arzoxifene has minimal side effects with powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and lipid profile .
    Arzoxifene
  • HY-B0005S1
    Toremifene-d6 hydrochloride

    Z-Toremifene-d6 hydrochloride; NK 622-d6 hydrochloride; FC-1157a-d6 hydrochloride

    		 Isotope-Labeled Compounds Estrogen Receptor/ERR Infection
    Toremifene-d6 (Z-Toremifene-d6) hydrochloride is deuterium labeled Toremifene. Toremifene is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
    Toremifene-d6 hydrochloride
  • HY-103457
    Y134

    		Estrogen Receptor/ERR Cancer
    Y134 is a selective and orally active oestrogen receptor (ER) modulator (SERM), exhibits potent antagonist activity at ERα and ERβ. Y134 shows 121.1-fold selectivity for ERα (Ki=0.09 nM) over ERβ (Ki=11.31 nM). Y134 inhibits oestrogen-stimulated proliferation of ER-positive human breast cancer cells .
    Y134
  • HY-A0036
    Bazedoxifene acetate
    5+ Cited Publications

    TSE-424 acetate

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene acetate (TSE-424 acetate) is an oral, nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene acetate can be used for the research of osteoporosis. Bazedoxifene acetate also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
    Bazedoxifene acetate
  • HY-A0031
    Bazedoxifene
    5+ Cited Publications

    TSE-424

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer .
    Bazedoxifene
  • HY-A0031A
    Bazedoxifene hydrochloride

    TSE-424 hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene hydrochloride (TSE-424 hydrochloride) is an oral active, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene hydrochloride can be used for the research of osteoporosis. Bazedoxifene hydrochloride acts as an inhibitor of IL-6/GP130 protein-protein interactions. Bazedoxifene hydrochloride can be used for the research of pancreatic cancer .
    Bazedoxifene hydrochloride
  • HY-13757A
    Tamoxifen
    Maximum Cited Publications
    83 Publications Verification

    ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
    Tamoxifen
  • HY-13724
    Pipendoxifene

    ERA-923

    		 Estrogen Receptor/ERR Cancer
    Pipendoxifene is a selective estrogen receptor modulator (SERM).
    Pipendoxifene
  • HY-13757
    Tamoxifen Citrate
    Maximum Cited Publications
    83 Publications Verification

    ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 µM and 1.8 µM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
    Tamoxifen Citrate
  • HY-U00178
    Idoxifene

    CB7432

    		 Estrogen Receptor/ERR Cancer
    Idoxifene (CB7432) is a novel tissue-specific selective estrogen receptor modulator (SERM).
    Idoxifene
  • HY-13724B
    Pipendoxifene hydrochloride

    		Estrogen Receptor/ERR Cancer
    Pipendoxifene hydrochloride is a selective estrogen receptor modulator (SERM) that can be used for the research of breast cancer .
    Pipendoxifene hydrochloride
  • HY-13738
    Raloxifene
    5+ Cited Publications

    Keoxifene; LY156758 free base; LY139481

    		 Estrogen Receptor/ERR Cancer
    Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research .
    Raloxifene
  • HY-B0723
    Ospemifene
    2 Publications Verification

    FC-1271a

    		 Estrogen Receptor/ERR Cancer
    Ospemifene is a non-estrogen selective estrogen receptor modulator (SERM), with Kis of 380 and 410 nM for estrogen receptor α (ERα) and ERβ, respectively. Ospemifene can be used for the research of vaginal atrophy and breast cancer .
    Ospemifene
  • HY-110201
    Estrogen receptor modulator 1

    		Estrogen Receptor/ERR Cancer
    Estrogen receptor modulator 1 (compound 18) is an orally active and selective estrogen receptor modulator (SERM), with a pIC50 of 0.46. Estrogen receptor modulator 1 induces regression of Tamoxifen-resistant, hormone independent xenograft tumors .
    Estrogen receptor modulator 1
  • HY-B0005A
    Toremifene
    5+ Cited Publications

    Z-Toremifene; NK 622 free base; FC-1157a free base

    		 Estrogen Receptor/ERR Infection Cancer
    Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
    Toremifene
  • HY-A0037
    Lasofoxifene

    CP-336156

    		 Estrogen Receptor/ERR Inflammation/Immunology Cancer
    Lasofoxifene (CP-336156) is an orally active and selective estrogen receptor modulator (SERM). Lasofoxifene exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene can be used for research of breast cancer and postmenopausal osteoporosis .
    Lasofoxifene
  • HY-B0005
    Toremifene citrate
    5+ Cited Publications

    Z-Toremifene citrate; NK 622; FC-1157a

    		 Estrogen Receptor/ERR Apoptosis Infection Cancer
    Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively .
    Toremifene citrate
  • HY-A0038
    Lasofoxifene tartrate
    3 Publications Verification

    CP-336156 tartrate

    		 Estrogen Receptor/ERR Endocrinology Cancer
    Lasofoxifene (CP-336156) tartrate is an orally active and selective estrogen receptor modulator (SERM) . Lasofoxifene tartrate exhibits an anti-osteoporotic function and also inhibits primary tumor growth and metastases. Lasofoxifene tartrate can be used for the research of breast cancer and postmenopausal osteoporosis .
    Lasofoxifene tartrate
  • HY-13738S
    Raloxifene-d4

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d4
  • HY-13738S2
    Raloxifene-d4 hydrochloride

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d4 (hydrochloride) is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d4 hydrochloride
  • HY-13738S3
    Raloxifene-d10

    		Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Raloxifene-d10 is the deuterium labeled Raloxifene. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[1].
    Raloxifene-d10
  • HY-16950
    4-Hydroxytamoxifen
    15+ Cited Publications

    (Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene

    		 Estrogen Receptor/ERR Cancer
    4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) induces CRISPR/Cas9 systems based on ER mediated nucleus translocation .
    4-Hydroxytamoxifen
  • HY-13738S4
    Raloxifene-d10-1

    Keoxifene-d10; LY156758(free base)-d10; LY139481-d10

    		 Estrogen Receptor/ERR Cancer
    Raloxifene-d10-1 is the deuterium labeled Raloxifene[1]. Raloxifene (Keoxifene) is a benzothiophene-derived selective estrogen receptor modulator (SERM). Raloxifene has estrogen-agonistic effects on bone and lipids and estrogen-antagonistic effects on the breast and uterus. Raloxifene is used for breast cancer and osteoporosis research[2].
    Raloxifene-d10-1
  • HY-B0005AS
    Toremifene-d6

    Z-Toremifene-d6; NK 622-d6 free base; FC-1157a-d6 free base

    		 Isotope-Labeled Compounds Estrogen Receptor/ERR Infection Cancer
    Toremifene-d6 is deuterium labeled Toremifene. Toremifene (Z-Toremifene) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
    Toremifene-d6
  • HY-B0005S
    Toremifene-d6 citrate

    		Estrogen Receptor/ERR Apoptosis Infection Cancer
    Toremifene-d6 (citrate) is the deuterium labeled Toremifene citrate. Toremifene citrate (Z-Toremifene citrate) is a second-generation selective estrogen-receptor modulator (SERM) in development for the prevention of osteoporosis. Toremifene citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.07 µM and 2.6 µM, respectively[1][2].
    Toremifene-d6 citrate
  • HY-126109
    (±)-8-Prenylnaringenin

    		Estrogen Receptor/ERR Apoptosis Metabolic Disease Endocrinology Cancer
    (±)-8-Prenylnaringenin, a natural prenylated flavonoid, is a potent phytoestrogen. (±)-8-Prenylnaringenin is an orally active selective estrogen receptor modulator (SERM) (Estrogen Receptor/ERR) that inhibits ERα and ERβ with IC50s of 57 nM and 68 nM, respectively. (±)-8-Prenylnaringenin has anticancer effects, and can be used for osteoporosis research .
    (±)-8-Prenylnaringenin
  • HY-116896
    LY117018

    		Estrogen Receptor/ERR Cancer
    LY117018, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 exerts antiproliferative effects on breast cancer cell lines .
    LY117018
  • HY-116896A
    LY117018 TFA

    		Estrogen Receptor/ERR Cancer
    LY117018 TFA, a Raloxifene analog, is a selective estrogen receptor modulator. LY117018 TFA exerts antiproliferative effects on breast cancer cell lines .
    LY117018 TFA
  • HY-A0031S
    Bazedoxifene-d4

    TSE-424-d4

    		 Isotope-Labeled Compounds Estrogen Receptor/ERR Cancer
    Bazedoxifene-d4 is deuterium labeled Bazedoxifene. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[1][2].
    Bazedoxifene-d4
  • HY-A0031S2
    Bazedoxifene-d4 acetate

    TSE-424-d4 acetate

    		 Estrogen Receptor/ERR Cancer
    Bazedoxifene-d4 (acetate) is the deuterium labeled Bazedoxifene[1]. Bazedoxifene (TSE-424) is an oral, BBB-penetrant nonsteroidal selective estrogen receptor modulator (SERM), with IC50s of 23 nM and 99 nM for ERα and ERβ, respectively. Bazedoxifene can be used for the research of osteoporosis. Bazedoxifene also acts as an inhibitor of IL-6/GP130 protein-protein interactions and can be used for the research of pancreatic cancer[2][3].
    Bazedoxifene-d4 acetate
  • HY-16023
    Acolbifene hydrochloride
    1 Publications Verification

    EM-652 hydrochloride; SCH 57068 hydrochloride

    		 Estrogen Receptor/ERR Cancer
    Acolbifene (EM-652) hydrochloride, an active metabolite of EM800, is an orally active, cancer-preventing selective estrogen receptor modulator (SERM). Acolbifene (EM-652) hydrochloride inhibits estradiol (E2)-induced transcriptional activity of ERα (IC50=2 nM) and ERβ (IC50=0.4 nM). Acolbifene (EM-652) hydrochloride exerts a potent and pure antiestrogenic action in the mammary gland and uterus. Anticarcinogenic properties .
    Acolbifene hydrochloride
  • HY-13757AS1
    Tamoxifen-d3

    ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3

    		 Estrogen Receptor/ERR Apoptosis Autophagy HSP Cancer
    Tamoxifen-d3 is the deuterium labeled Tamoxifen[1]. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells[2][3][4]. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively[6]. Tamoxifen activates autophagy and induces apoptosis[5]. Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse[7].
    Tamoxifen-d3
  • HY-13757AR
    Tamoxifen (Standard)
    75+ Cited Publications

    ICI 47699(Standard); (Z)-Tamoxifen(Standard); trans-Tamoxifen (Standard)

    		 Estrogen Receptor/ERR HSP Autophagy Apoptosis Cancer
    Tamoxifen (Standard) is the analytical standard of Tamoxifen. This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
    Tamoxifen (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: